原发性醛固酮增多症诊断中CXCR4受体显像的临床应用专家共识(2022)

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

原发性醛固酮增多症诊断中CXCR4受体显像的临床应用专家共识(2022)

中国医师协会泌尿外科医师分会肾上腺性高血压外科协作组, 中华医学会内分泌学分会肾上腺学组, 中华医学会核医学分会PET学组

文章导航 > 协和医学杂志 > 2022 > 13(6): 986-991

中国医师协会泌尿外科医师分会肾上腺性高血压外科协作组, 中华医学会内分泌学分会肾上腺学组, 中华医学会核医学分会PET学组. 原发性醛固酮增多症诊断中CXCR4受体显像的临床应用专家共识(2022)[J]. 协和医学杂志, 2022, 13(6): 986-991. doi: 10.12290/xhyxzz.2022-0584

引用本文:

中国医师协会泌尿外科医师分会肾上腺性高血压外科协作组, 中华医学会内分泌学分会肾上腺学组, 中华医学会核医学分会PET学组. 原发性醛固酮增多症诊断中CXCR4受体显像的临床应用专家共识(2022)[J]. 协和医学杂志, 2022, 13(6): 986-991. doi: 10.12290/xhyxzz.2022-0584

Chinese Urological Doctor Association Adrenal Hypertension Surgery Collaborative Organization Adrenal Group, Chinese Society of Endocrinology PET group, Chinese Society of Nuclear Medicine. Consensus on Clinical Application of the CXCR4-targeted Imaging in the Diagnosis of Primary Aldosteronism(2022)[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 986-991. doi: 10.12290/xhyxzz.2022-0584

Citation:

Chinese Urological Doctor Association Adrenal Hypertension Surgery Collaborative Organization Adrenal Group, Chinese Society of Endocrinology PET group, Chinese Society of Nuclear Medicine. Consensus on Clinical Application of the CXCR4-targeted Imaging in the Diagnosis of Primary Aldosteronism(2022)[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 986-991. doi: 10.12290/xhyxzz.2022-0584

中国医师协会泌尿外科医师分会肾上腺性高血压外科协作组, 中华医学会内分泌学分会肾上腺学组, 中华医学会核医学分会PET学组. 原发性醛固酮增多症诊断中CXCR4受体显像的临床应用专家共识(2022)[J]. 协和医学杂志, 2022, 13(6): 986-991. doi: 10.12290/xhyxzz.2022-0584

引用本文:

中国医师协会泌尿外科医师分会肾上腺性高血压外科协作组, 中华医学会内分泌学分会肾上腺学组, 中华医学会核医学分会PET学组. 原发性醛固酮增多症诊断中CXCR4受体显像的临床应用专家共识(2022)[J]. 协和医学杂志, 2022, 13(6): 986-991. doi: 10.12290/xhyxzz.2022-0584

Chinese Urological Doctor Association Adrenal Hypertension Surgery Collaborative Organization Adrenal Group, Chinese Society of Endocrinology PET group, Chinese Society of Nuclear Medicine. Consensus on Clinical Application of the CXCR4-targeted Imaging in the Diagnosis of Primary Aldosteronism(2022)[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 986-991. doi: 10.12290/xhyxzz.2022-0584

Citation:

Chinese Urological Doctor Association Adrenal Hypertension Surgery Collaborative Organization Adrenal Group, Chinese Society of Endocrinology PET group, Chinese Society of Nuclear Medicine. Consensus on Clinical Application of the CXCR4-targeted Imaging in the Diagnosis of Primary Aldosteronism(2022)[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 986-991. doi: 10.12290/xhyxzz.2022-0584

原发性醛固酮增多症诊断中CXCR4受体显像的临床应用专家共识(2022)

doi: 10.12290/xhyxzz.2022-0584

基金项目:

中央高水平医院临床科研业务费 2022-PUMCH-C-028

中央高水平医院临床科研业务费 2022-PUMCH-B-010

中国医学科学院创新工程 2022-I2M-JB-001

通信作者: 张玉石¹, E-mail: zhangyushi@126.com
童安莉², E-mail: tonganli@hotmail.com
霍力³, E-mail: huoli@pumch.cn
1 中国医学科学院北京协和医院泌尿外科，北京 100730
2 中国医学科学院北京协和医院内分泌科，北京 100730
3 中国医学科学院北京协和医院核医学科，北京 100730

中图分类号: R586.2+4
计量
- 文章访问数: 840
- HTML全文浏览量: 143
- PDF下载量: 381
- 被引次数: 0
出版历程
- 收稿日期: 2022-10-09
- 录用日期: 2022-10-25
- 网络出版日期: 2022-11-07
- 刊出日期: 2022-11-30

Consensus on Clinical Application of the CXCR4-targeted Imaging in the Diagnosis of Primary Aldosteronism(2022)

Funds:

National High Level Hospital Clinical Research Funding 2022-PUMCH-C-028

National High Level Hospital Clinical Research Funding 2022-PUMCH-B-010

CAMS Innovation Fund for Medical Sciences 2022-I2M-JB-001

摘要: 原发性醛固酮增多症的分型诊断是临床工作的重点和难点, 越来越多的临床证据表明, 靶向CXCR4的⁶⁸Ga-Pentixafor PET/CT核素显像可辅助原发性醛固酮增多症的分型。基于国内外最新研究证据, 经多学科专家组深入讨论, 在核素显像方法和结果判读, 以及其对治疗方案的指导和预后评估方面达成了一致意见。本共识为规范国内⁶⁸Ga-Pentixafor PET/CT显像, 提高我国原发性醛固酮增多症诊疗水平提供了重要依据。
- 原发性醛固酮增多症 /
- CXCR4受体 /
- ⁶⁸Ga-Pentixafor PET/CT /
- 专家共识
Abstract: Subtype classification of primary aldosteronism is important but challenging. Increasing evidence has shown that ⁶⁸Ga-Pentixafor PET/CT imaging which targets CXCR4 is beneficial to the subtype classification of primary aldosteronism. Based on all the available evidence, and after in-depth discussion of a group of multi-disciplinary experts, a consensus has been established, which covers imaging technology, interpretation of results of CXCR4 imaging, and the guidance to the choice of the treatment and prognosisevaluation. The consensus is helpful for standardizing ⁶⁸Ga-Pentixafor PET/CT imaging and promoting a better diagnosis procedure in primary aldosteronism.
- primary aldosteronism /
- CXCR4 receptor /
- ⁶⁸Ga-Pentixafor PET/CT /
- expert consensus
注释:

作者贡献：张玉石、童安莉、霍力牵头制订共识框架，组建共识制订工作组，并审阅定稿；丁洁、郑国洋、高寅洁复习文献，起草共识初稿；所有专家组成员参与讨论、修订共识初稿，并最后定稿；李启富、张少玲、刘龙飞、朱育春、卢琳、陈适、孟哲参与共识内容的修订。

利益冲突：所有参与本共识制订的人员均声明不存在利益冲突

专家组 (按姓氏首字母排序)

常晓燕(北京协和医院病理科)，陈适(北京协和医院内分泌科)，何勇(武汉大学中南医院核医学科)，胡硕(中南大学湘雅医院核医学科)，霍力(北京协和医院核医学科)，纪志刚(北京协和医院泌尿外科)，李汉忠(北京协和医院泌尿外科)，李启富(重庆医科大学附属第一医院内分泌科)，刘龙飞(中南大学湘雅医院泌尿外科)，卢琳(北京协和医院内分泌科)，马晓伟(中南大学湘雅二医院核医学科)，孟哲(武汉大学中南医院泌尿外科)，缪蔚冰(福建医科大学附属第一医院核医学科)，庞华(重庆医科大学附属第一医院核医学科)，邱玲(北京协和医院检验科)，童安莉(北京协和医院内分泌科)，魏强(四川大学华西医院泌尿外科)，徐浩(暨南大学附属第一医院核医学科)，曾天舒(华中科技大学同济医学院附属协和医院内分泌科)，张波(中日友好医院内分泌科)，张少玲(中山大学孙逸仙纪念医院内分泌科)，张玉石(北京协和医院泌尿外科)，赵军(上海东方医院核医学科)，周颋(北京协和医院内分泌科)，朱育春(四川大学华西医院泌尿外科)

执笔人：丁洁(北京协和医院核医学科)，郑国洋(北京协和医院泌尿外科)，高寅洁(北京协和医院内分泌科)

参考文献(15)

[1]	Funder JW, Carey RM, Mantero F, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline[J]. J Clin Endocrinol Metab, 2016, 101: 1889-1916. doi: 10.1210/jc.2015-4061
[2]	Mulatero P, Monticone S, Deinum J, et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension[J]. J Hypertens, 2020, 38: 1919-1928. doi: 10.1097/HJH.0000000000002510
[3]	Wang H, Wang F, Zhang Y, et al. Surgical Outcomes of Aldosterone-Producing Adenoma on the Basis of the Histopathological Findings[J]. Front Endocrinol (Lausanne), 2021, 12: 663096. doi: 10.3389/fendo.2021.663096
[4]	Mulatero P, Sechi LA, Williams T A, et al. Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension[J]. J Hypertens, 2020, 38: 1929-1936. doi: 10.1097/HJH.0000000000002520
[5]	Walenkamp A, Lapa C, Herrmann K, et al. CXCR4 Ligands: The Next Big Hit?[J]. J Nucl Med, 2017, 58: 77S-82S. doi: 10.2967/jnumed.116.186874
[6]	Heinze B, Fuss CT, Mulatero P, et al. Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma[J]. Hypertension, 2018, 71: 317-325. doi: 10.1161/HYPERTENSIONAHA.117.09975
[7]	Ding J, Zhang Y, Wen J, et al. Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism[J]. Eur J Nucl Med Mol Imaging, 2020, 47: 2656-2665. doi: 10.1007/s00259-020-04722-0
[8]	Ding J, Tong A, Zhang Y, et al. Functional Characterization of Adrenocortical Masses in Nononcologic Patients Using (68)Ga-Pentixafor[J]. J Nucl Med, 2022, 63: 368-375. doi: 10.2967/jnumed.121.261964
[9]	Ding J, Tong A, Zhang Y, et al. Intense ⁶⁸Ga-Pentixafor Activity in Aldosterone-Producing Adrenal Adenomas[J]. Clin Nucl Med, 2020, 45: 336-339. doi: 10.1097/RLU.0000000000002946
[10]	Gao Y, Ding J, Cui Y, et al. Functional nodules in primary aldosteronism: identification of CXCR4 expression with (68)Ga-Pentixafor PET/CT[J]. Eur Radiol, 2022. doi: 10.1007/s00330-022-09058-x.
[11]	Song Y, Yang J, Shen H, et al. Development and validation of model for sparing adrenal venous sampling in diagnosing unilateral primary aldosteronism[J]. J Hypertens, 2022, 40: 1692-1701. doi: 10.1097/HJH.0000000000003197
[12]	Fu B, Zhang X, Wang GX, et al. Long-term results of a prospective, randomized trial comparing retroperitoneoscopic partial versus total adrenalectomy for aldosterone producing adenoma[J]. J Urol, 2011, 185: 1578-1582. doi: 10.1016/j.juro.2010.12.051
[13]	中华医学会内分泌学分会. 原发性醛固酮增多症诊断治疗的专家共识(2020版)[J]. 中华内分泌代谢杂志, 2020, 36: 727-736. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGGZ202111003.htm Chinese Society of Endocrinology. Expert consensus on the diagnosis and treatment of primary aldosteronism (2020)[J]. Zhonghua Neifenmi Daixie Zazhi, 2020, 36: 727-736. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGGZ202111003.htm
[14]	Steichen O, Zinzindohoué F, Plouin PF, et al. Outcomes of adrenalectomy in patients with unilateral primary aldosteronism: a review[J]. Horm Metab Res, 2012, 44: 221-227. doi: 10.1055/s-0031-1299681
[15]	Williams TA, Lenders JWM, Mulatero P, et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort[J]. Lancet Diabetes Endocrinol, 2017, 5: 689-699. doi: 10.1016/S2213-8587(17)30135-3

资源附件(0)

WeChat

点击查看大图

计量

文章访问数: 840
HTML全文浏览量: 143
PDF下载量: 381
被引次数: 0

/

下载: 全尺寸图片幻灯片

分享

用微信扫码二维码

分享至好友和朋友圈

返回

地址：	北京市东城区帅府园1号北京协和医院老楼7号楼 3层302室《协和医学杂志》编辑部
电话：	010-69154261/4262
E - mail：	medj@pumch.cn mjpumch@126.com
期刊网站版权所有：	《协和医学杂志》编辑部京ICP备 11002662

本系统由北京仁和汇智信息技术有限公司开发

x 关闭永久关闭

【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！